This month’s Back to Basics summarizes the main features of the key direct oral anticoagulants (DOACs or NOACS). These drugs are becoming a standard therapy in many settings including stroke prevention, management of deep vein thrombosis and pulmonary embolism, and prevention of venous thromboembolism following hip and knee replacement.
An educational workshop at the 2017 Issues & Answers conference highlighted heart valve disease and the important role of primary care in its effective management. Across the UK approximately 1.5 million people >65 years are currently affected by the disease numbers predicted to more than double to 3.3 million by 2056.
This month’s Back to Basics feature is a patient information card that is included in the 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. The card can be folded into pocket size and is crucial both for the patient and for healthcare providers. The EHRA states that this generic and universal card can serve all patients under NOAC therapy.